- Home
- FMST vs BOLD Comparison
FMST vs BOLD Comparison
Compare FMST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMST | BOLD |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Canada | United States |
| Employees | 2 | N/A |
| Industry | Other Metals and Minerals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 25.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | FMST | BOLD |
|---|---|---|
| Price | $1.97 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 139.4K | 55.8K |
| Earning Date | 02-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.96 |
| 52 Week High | $5.74 | $1.78 |
Technical Indicators
Market Signals| Indicator | FMST | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | 54.72 |
| Support Level | $1.73 | $1.15 |
| Resistance Level | $2.52 | $1.19 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 3.62 | 87.50 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.